The U.S. Court of Appeals for the Federal Circuit has upheld a Patent Trial and Appeal Board (PTAB) decision, ruling that claims in a United Therapeutics Corp. patent for a high blood pressure drug were invalid on the grounds of obviousness. The challenge was brought forth by Liquidia Technologies, despite the petition containing an expert declaration that lacked the required oath. Legal professionals can delve into further details of this case here.